Nordic Stomach Cancer Market Size & Outlook, 2025-2033
Nordic Stomach Cancer Market Insights
- As highlighted in Reed Intelligence analysis, the Nordic Stomach Cancer Market, worth USD 59.68 Million in 2024, is forecasted to achieve USD 180.9 Million by 2033.
- The Nordic market is anticipated to grow at a CAGR of 13.2% during the period 2026–2033.
- By 2024, Adenocarcinoma represented the largest share of the By Type market size.
- Others is expected to remain the key growth driver within By Type, registering the fastest CAGR during the forecast period.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2024, Nordic represented 1.72% of the overall global Stomach Cancer Market size.
- United States is projected to lead the global Stomach Cancer Market size by 2033.
- Across Europe, Germany is anticipated to hold the dominant position in market size by 2033.
- France is forecasted to expand at the fastest pace in Europe, attaining USD 694.26 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 59.68 Million |
| Market Size In 2033 | USD 180.9 Million |
| Largest segment | Adenocarcinoma |
| Units | Revenue in USD Million |
| CAGR | 13.2% (2025-2033) |
| Segmnetation Covered | |
| By Type |
|
| By Therapy Type |
|
| By End-User |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Nordic Stomach Cancer Market By Type 2025-2033 (USD Million)
| By Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adenocarcinoma | XX.x | XX.x | XX.x | 21.67 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Lymphoma | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Gastrointestinal Stromal Tumor | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Carcinoid Tumor | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Nordic Stomach Cancer Market By Therapy Type 2025-2033 (USD Million)
| By Therapy Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chemotherapy | XX.x | XX.x | XX.x | 20.94 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Targeted Therapy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Immunotherapy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Radiation Therapy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Surgery | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Nordic Stomach Cancer Market By End-User 2025-2033 (USD Million)
| By End-User | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ambulatory Surgery Centers | XX.x | XX.x | XX.x | 32.69 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Hospitals and Specialty Clinics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Other End-Users | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
